Now at #EANO2026 on #radiotherapy in glioblastoma 🧠: ➡️ #FET-PET-informed target volumes were larger than MRI-only volumes ➡️ MRI-based plans showed lower coverage 📄Take-home: MRI-only planning may under-cover disease, but whether this translates into better tumour control still needs to be shown

In the #UNITED/MR-guided adaptive #Radiotherapy for high-grade glioma: ➡️ 5-mm adaptive CTV margins, with target volumes 40-71% smaller than conventional volumes ➡️ Marginal failure low (4%) ➡️ Higher lymphocyte counts at the end of RT ➡️ Treatment-induced severe lymphopenia: 6.8% vs 14.9% #EANO2026

Interesting data from #STERIMGLI at #EANO2026 on #re-irradiation + #durvalumab for recurrent glioblastoma: ➡️ HF-SRT 24 Gy/3 fx ➡️ Primary OS endpoint not met in ITT population (16.1 vs 13.3 months) ➡️ QoL and cognition maintained ➡️ Exploratory analyses suggest a stronger OS in WHO 2021 glioblastoma

Poster session time at #EANO2026! Don’t miss the opportunity to have engaging discussions with presenters and colleagues 🗣️ Here few posters that caught my attention 👇🏻 Go and check it out yourselves #RadiationOncology #NeuroOncology

Prof. Susan Short made the Pro case for #radiotherapy + chemotherapy in every patient with grade 3 IDH-mutant #glioma. A great debate around which treatments we can, and should, deliver to this population #EANO2026

📢 Just presented at #EANO2026 – now published in Neuro-Oncology! The study “Potentially Inappropriate Care at the End of Life in Patients with Glioblastoma: A Single-Center Observational Cohort Study”, presented by first author Robin Pieterman, is now available open access. 🔗 doi.org/10.1093/neuo...

#EANO2026 continues in #Rome on another beautiful day ☀️ This morning, don’t miss: ➡️selected abstracts sessions 📄 ➡️pro/contra debate on chemo-RT for IDH-mutant grade 3 gliomas, from Susan Short and Martin van den Bent 🧠 Looking forward to another full day of science and discussion! #radiotherapy

Poster session time at #EANO2026! 🧠 If you’re around, don’t miss the #Radiotherapy poster section as well. Lots of interesting work on RT, from quality assurance, dose, and treatment #RadiationOncology #NeuroOncology #RTQA #Radiotherapy

At #EANO2026, #EORTC 2227-LEGATO trial is addressing an important question: does adding #reirradiation to lomustine improve outcomes compared with lomustine alone in #glioblastoma? Hopefully this phase III trial will generate the evidence needed to define the role of reRT at first progression.

Starting now at #EANO2026: the EANO-EORTC session! Looking forward to Prof. Weller’s talk on trial design pitfalls, followed by presentations of ongoing #EORTC trials: GLIO-RARE, LEGATO, LUMEN and VIGOR. A very relevant session on how we design better neuro-oncology trials, not just new treatments.

ROAM in Rome at #EANO2026 ! Results from the EORTC 1308/ROAM trial: in resected WHO grade 2 #meningioma, adjuvant #radiotherapy improved 5-year DFS compared with observation (79.9% vs 62.3%; HR 0.51). Important evidence for a long-debated question! @eanoassociation.bsky.social @eortc.org

#EANO2026 Chair Giuseppe Minniti takes the stage to officially open the congress, kicking off a packed programme with 44 scientific sessions, poster presentations, and contributions from scientific partners such as @eortc.org #radiotherapy #EANO #EORTC

#EANO2026 Educational Day is underway, and later today don’t miss the Pro/Con session on two key radiation oncology questions: proton therapy in IDH-mutant gliomas and local vs systemic treatment for active breast cancer brain metastases 🧠 #RadiationOncology #NeuroOncology

🧠 EANO-ESTRO Joint Session at #EANO2026 Join “Toward Precision and Cognitive-Sparing Radiotherapy in Gliomas” and hear from the ESTRO speakers 📅 27 Sep | 🕘 09:00–10:30 CEST 📍 Sinopoli Hall, Rome 👉 https://bit.ly/4hJiFy7 #ESTRO #EANO #Radonc